Prevalence of hepatitis C virus infection in patients with cardiomyopathy

Boyella, Vijaya; Onyebueke, Ikenna F.; Farraj, Najabh; Graham-Hill, Suzette; Younis, Cherif El; Bergasa, Nora V.

doi:10.1016/s1665-2681(19)31787-9

Cited by 7 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C virus (HCV) can be isolated from the myocardium of patients with myocarditis and cardiomyopathy and the mechanisms of damages the myocardium by the virus have not been elucidated [11][12][13][14] .…”

Section: Introductionmentioning

confidence: 99%

Influence of different regimens of direct acting antiviral agents (DAAS) with or without ribavirin used for chronic hepatitis C treatment on the cardiac muscles in Egypt

El-Adawy¹,

Altonbary²,

Hakim³

et al. 2018

J. Med. Res.

View full text Add to dashboard Cite

Background: Infection with Hepatitis C virus (HCV) is of significant public-health encumbrance in Egyptian population that afford the considerable predominance rate worldwide. This study was aimed to evaluate the correlation between the different treatment regimens on cardiac cardiovascular complication. Methods and Results: In this study, 390 patients diagnosed as HCV infection in Mansoura, Egypt were sectioned into four groups. Group A treated with ledipasvir and sofosbuvir (LED +SOF), group B received simepriver and sofosbuvir (SIM+SOF), group C treated sofosbuvir and daclatasvir (Sof+DCV) and group D received with triple combination therapy of sofosbuvir, daclatasvir and ribavirin (SOF+DCV+ RBV). The full hepatological assessment, blood analysis and clinical investigation were performed. All participants went through a cardiac assessment for detection of development of cardiovascular changes. There was significant elevation in levels of AST, ALT, serum albumin, platelet count, heamoglobin concentration and the Child classification between the studied groups. There was significant difference in the CMR results during the study especially in fourth group (SOF+DCV+RBV) group. No statistical difference regarding pericardial effusion. There was significant elevation of cardiac enzymes (Troponin, CK MB, BNP ) mostly in all groups especially in the fourth group (SOF+DCV+ RBV) with one outlier in SOF+DCV group and 3 outliers presented mainly with BNP (P value <0.001). Conclusions: DAAs are proved its efficacy in management of chronic HCV in Egyptian patients as standard of care for hepatitis C treatment. Also tested its safety on the heart with most of its applied regimens.

show abstract

Section: Introductionmentioning

confidence: 99%

Influence of different regimens of direct acting antiviral agents (DAAS) with or without ribavirin used for chronic hepatitis C treatment on the cardiac muscles in Egypt

El-Adawy¹,

Altonbary²,

Hakim³

et al. 2018

J. Med. Res.

View full text Add to dashboard Cite

show abstract

“…Chronic infection by HCV (family Flaviviridae) is also associated with CVDs [77,78]. Similar to cardioviruses, HCV RNA expression is driven by IRES-mediated translation initiation [77].…”

Section: Iressmentioning

confidence: 99%

“…Chronic infection by HCV (family Flaviviridae) is also associated with CVDs [77,78]. Similar to cardioviruses, HCV RNA expression is driven by IRES-mediated translation initiation [77]. Under cellular stress conditions, specific domains of HCV IRES interact with the small ribosomal subunit and the initiation factors eIF3 and eIF5B (Figure 1, left), allowing expression of viral RNA [79].…”

Section: Iressmentioning

confidence: 99%

Effects of Oxidative Stress on Protein Translation: Implications for Cardiovascular Diseases

Ghosh

Shcherbik

2020

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are a group of disorders that affect the heart and blood vessels. Due to their multifactorial nature and wide variation, CVDs are the leading cause of death worldwide. Understanding the molecular alterations leading to the development of heart and vessel pathologies is crucial for successfully treating and preventing CVDs. One of the causative factors of CVD etiology and progression is acute oxidative stress, a toxic condition characterized by elevated intracellular levels of reactive oxygen species (ROS). Left unabated, ROS can damage virtually any cellular component and affect essential biological processes, including protein synthesis. Defective or insufficient protein translation results in production of faulty protein products and disturbances of protein homeostasis, thus promoting pathologies. The relationships between translational dysregulation, ROS, and cardiovascular disorders will be examined in this review.

show abstract

“…Fulminant MC with congestive HF, hypotension and death may be a consequence of HVC infection but very rare [67,68]. A recent study of 48 nonischemic DCM patients and depressed systolic function chronic HCV found 4.8% had serum antibodies to the HVC and 2.4% with HCV RNA [69]. Characteristics pathologic features associated with HVC infection include minute foci of necrosis of isolated muscle bundles usually surrounded by lymphocytes and diffuse serious inflammation [70].…”

Section: Hepatitis C Virusmentioning

confidence: 99%

Viral Cardiomyopathy: A Review of Clinical Status and Meta-Analysis of Diagnosis and Clinical Management

Albakri¹

2019

2516-7138

View full text Add to dashboard Cite

From an aetiological standpoint, viral cardiomyopathy represents an uncommon subtype of non-inflammatory dilated cardiomyopathy. The most common aetiologic agents are enteroviruses, adenoviruses and erythroviruses. Pathogenesis depends on the causative virus. Enteroviruses and adenoviruses infect and injure the cardiomyocyte through cytopathic effect and immune-mediated damage leading to cardiac remodelling, myocarditis and ultimately cardiomyopathy. Erythroviruses infect and injure the vascular endothelial cells resulting in macrovascular dysfunction. Typical clinical presentation is heart failure, arrhythmias and chest pains. Clinical diagnosis requires the presence of electrocardiographic abnormalities, markers of myocardial necrosis or evidence of functional/structural ventricular abnormalities accompanied by at least one physical sign or clinical symptom. However, endomyocardial biopsy remains the reference standard but increased risks of complications and the need for highly experienced operators limits its widespread use. The available clinical management strategies are standard heart failure medication for the management of cardiac dysfunction and antiarrhythmic drugs for those with ventricular arrhythmias. Patients with refractory symptoms greater than six months despite optimal medical therapy and with biopsy-proven virus negative myocardium may benefit from supplementary immunosuppressive therapy. However, largescale and long-term prospective randomized clinical trials are warranted to determine long-term benefits of immunosuppression.

show abstract

Prevalence of hepatitis C virus infection in patients with cardiomyopathy

Cited by 7 publications

References 21 publications

Influence of different regimens of direct acting antiviral agents (DAAS) with or without ribavirin used for chronic hepatitis C treatment on the cardiac muscles in Egypt

Influence of different regimens of direct acting antiviral agents (DAAS) with or without ribavirin used for chronic hepatitis C treatment on the cardiac muscles in Egypt

Effects of Oxidative Stress on Protein Translation: Implications for Cardiovascular Diseases

Viral Cardiomyopathy: A Review of Clinical Status and Meta-Analysis of Diagnosis and Clinical Management

Contact Info

Product

Resources

About